Cargando…
Prognostic value of tumour volume in patients with a poor Karnofsky performance status scale – a bicentric retrospective study
BACKROUND: Median overall survival (OS) after diagnosis of glioblastoma (GBM) remains 15 months amongst patients receiving aggressive surgical resection, chemotherapy and irradiation. Treatment of patients with a poor preoperative Karnofsky Performance Status Scale (KPSS) is still controversial. The...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591917/ https://www.ncbi.nlm.nih.gov/pubmed/34781889 http://dx.doi.org/10.1186/s12883-021-02424-0 |
_version_ | 1784599356529180672 |
---|---|
author | Barz, Melanie Gerhardt, Julia Bette, Stefanie Aftahy, A. Kaywan Huber, Thomas Combs, Stephanie E. Ryang, Yu-Mi Wiestler, Benedikt Skardelly, Marco Gepfner-Tuma, Irina Behling, Felix Schmidt-Graf, Friederike Meyer, Bernhard Gempt, Jens |
author_facet | Barz, Melanie Gerhardt, Julia Bette, Stefanie Aftahy, A. Kaywan Huber, Thomas Combs, Stephanie E. Ryang, Yu-Mi Wiestler, Benedikt Skardelly, Marco Gepfner-Tuma, Irina Behling, Felix Schmidt-Graf, Friederike Meyer, Bernhard Gempt, Jens |
author_sort | Barz, Melanie |
collection | PubMed |
description | BACKROUND: Median overall survival (OS) after diagnosis of glioblastoma (GBM) remains 15 months amongst patients receiving aggressive surgical resection, chemotherapy and irradiation. Treatment of patients with a poor preoperative Karnofsky Performance Status Scale (KPSS) is still controversial. Therefore, we retrospectively assessed the outcome after surgical treatment in patients with a KPSS of ≤60%. METHODS: We retrospectively included patients with a de-novo glioblastoma WHO °IV and preoperative KPSS ≤60%, who underwent surgery at two neurosurgical centres between September 2006 and March 2016. We recorded pre- and postoperative tumour volume, pre- and postoperative KPSS, OS, age and MGMT promoter status. RESULTS: One hundred twenty-three patients (58 females/65 males, mean age 67.4 ± 13.4 years) met the inclusion criteria. Seventy-five of the 123 patients (61%) underwent surgical resection. 48/123 patients (39%) received a biopsy. The median preoperative and postoperative tumour volume of all patients was 33.0 ± 31.3 cm(3) (IR 15.0–56.5cm(3)) and 3.1 ± 23.8 cm(3) (IR 0.2–15.0 cm(3)), respectively. The median KPSS was 60% (range 20–60%) preoperatively and 50% (range 0–80%) postoperatively. Patients who received a biopsy showed a median OS for patients who received a biopsy only was 3.0 months (95% CI 2.0–4.0 months), compared to patients who had a resection and had a median OS of 8 months (95% CI 3.1–12.9 months). Age (p < 0.001, HR: 1.045 [95% CI 1.022–1.068]), postoperative tumour volume (p = 0.02, HR: 1.016 [95% CI 1.002–1.029]) and MGMT promotor status (p = 0.016, HR: 0.473 [95% CI 0.257–0.871]) were statistically significant in multivariate analysis. In subgroup analyses only age was shown as a significant prognostic factor in multivariate analyses for patients receiving surgery (p < 0.001, HR: 1.046 [95% CI 1.022–1.072]). In the biopsy group no significant prognostic factors were shown in multivariate analysis. CONCLUSION: GBM patients with a preoperative KPSS of ≤60% might profit from surgical reduction of tumour burden. |
format | Online Article Text |
id | pubmed-8591917 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-85919172021-11-15 Prognostic value of tumour volume in patients with a poor Karnofsky performance status scale – a bicentric retrospective study Barz, Melanie Gerhardt, Julia Bette, Stefanie Aftahy, A. Kaywan Huber, Thomas Combs, Stephanie E. Ryang, Yu-Mi Wiestler, Benedikt Skardelly, Marco Gepfner-Tuma, Irina Behling, Felix Schmidt-Graf, Friederike Meyer, Bernhard Gempt, Jens BMC Neurol Research Article BACKROUND: Median overall survival (OS) after diagnosis of glioblastoma (GBM) remains 15 months amongst patients receiving aggressive surgical resection, chemotherapy and irradiation. Treatment of patients with a poor preoperative Karnofsky Performance Status Scale (KPSS) is still controversial. Therefore, we retrospectively assessed the outcome after surgical treatment in patients with a KPSS of ≤60%. METHODS: We retrospectively included patients with a de-novo glioblastoma WHO °IV and preoperative KPSS ≤60%, who underwent surgery at two neurosurgical centres between September 2006 and March 2016. We recorded pre- and postoperative tumour volume, pre- and postoperative KPSS, OS, age and MGMT promoter status. RESULTS: One hundred twenty-three patients (58 females/65 males, mean age 67.4 ± 13.4 years) met the inclusion criteria. Seventy-five of the 123 patients (61%) underwent surgical resection. 48/123 patients (39%) received a biopsy. The median preoperative and postoperative tumour volume of all patients was 33.0 ± 31.3 cm(3) (IR 15.0–56.5cm(3)) and 3.1 ± 23.8 cm(3) (IR 0.2–15.0 cm(3)), respectively. The median KPSS was 60% (range 20–60%) preoperatively and 50% (range 0–80%) postoperatively. Patients who received a biopsy showed a median OS for patients who received a biopsy only was 3.0 months (95% CI 2.0–4.0 months), compared to patients who had a resection and had a median OS of 8 months (95% CI 3.1–12.9 months). Age (p < 0.001, HR: 1.045 [95% CI 1.022–1.068]), postoperative tumour volume (p = 0.02, HR: 1.016 [95% CI 1.002–1.029]) and MGMT promotor status (p = 0.016, HR: 0.473 [95% CI 0.257–0.871]) were statistically significant in multivariate analysis. In subgroup analyses only age was shown as a significant prognostic factor in multivariate analyses for patients receiving surgery (p < 0.001, HR: 1.046 [95% CI 1.022–1.072]). In the biopsy group no significant prognostic factors were shown in multivariate analysis. CONCLUSION: GBM patients with a preoperative KPSS of ≤60% might profit from surgical reduction of tumour burden. BioMed Central 2021-11-15 /pmc/articles/PMC8591917/ /pubmed/34781889 http://dx.doi.org/10.1186/s12883-021-02424-0 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Barz, Melanie Gerhardt, Julia Bette, Stefanie Aftahy, A. Kaywan Huber, Thomas Combs, Stephanie E. Ryang, Yu-Mi Wiestler, Benedikt Skardelly, Marco Gepfner-Tuma, Irina Behling, Felix Schmidt-Graf, Friederike Meyer, Bernhard Gempt, Jens Prognostic value of tumour volume in patients with a poor Karnofsky performance status scale – a bicentric retrospective study |
title | Prognostic value of tumour volume in patients with a poor Karnofsky performance status scale – a bicentric retrospective study |
title_full | Prognostic value of tumour volume in patients with a poor Karnofsky performance status scale – a bicentric retrospective study |
title_fullStr | Prognostic value of tumour volume in patients with a poor Karnofsky performance status scale – a bicentric retrospective study |
title_full_unstemmed | Prognostic value of tumour volume in patients with a poor Karnofsky performance status scale – a bicentric retrospective study |
title_short | Prognostic value of tumour volume in patients with a poor Karnofsky performance status scale – a bicentric retrospective study |
title_sort | prognostic value of tumour volume in patients with a poor karnofsky performance status scale – a bicentric retrospective study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591917/ https://www.ncbi.nlm.nih.gov/pubmed/34781889 http://dx.doi.org/10.1186/s12883-021-02424-0 |
work_keys_str_mv | AT barzmelanie prognosticvalueoftumourvolumeinpatientswithapoorkarnofskyperformancestatusscaleabicentricretrospectivestudy AT gerhardtjulia prognosticvalueoftumourvolumeinpatientswithapoorkarnofskyperformancestatusscaleabicentricretrospectivestudy AT bettestefanie prognosticvalueoftumourvolumeinpatientswithapoorkarnofskyperformancestatusscaleabicentricretrospectivestudy AT aftahyakaywan prognosticvalueoftumourvolumeinpatientswithapoorkarnofskyperformancestatusscaleabicentricretrospectivestudy AT huberthomas prognosticvalueoftumourvolumeinpatientswithapoorkarnofskyperformancestatusscaleabicentricretrospectivestudy AT combsstephaniee prognosticvalueoftumourvolumeinpatientswithapoorkarnofskyperformancestatusscaleabicentricretrospectivestudy AT ryangyumi prognosticvalueoftumourvolumeinpatientswithapoorkarnofskyperformancestatusscaleabicentricretrospectivestudy AT wiestlerbenedikt prognosticvalueoftumourvolumeinpatientswithapoorkarnofskyperformancestatusscaleabicentricretrospectivestudy AT skardellymarco prognosticvalueoftumourvolumeinpatientswithapoorkarnofskyperformancestatusscaleabicentricretrospectivestudy AT gepfnertumairina prognosticvalueoftumourvolumeinpatientswithapoorkarnofskyperformancestatusscaleabicentricretrospectivestudy AT behlingfelix prognosticvalueoftumourvolumeinpatientswithapoorkarnofskyperformancestatusscaleabicentricretrospectivestudy AT schmidtgraffriederike prognosticvalueoftumourvolumeinpatientswithapoorkarnofskyperformancestatusscaleabicentricretrospectivestudy AT meyerbernhard prognosticvalueoftumourvolumeinpatientswithapoorkarnofskyperformancestatusscaleabicentricretrospectivestudy AT gemptjens prognosticvalueoftumourvolumeinpatientswithapoorkarnofskyperformancestatusscaleabicentricretrospectivestudy |